米托蒽醌
耐受性
医学
心脏毒性
视神经脊髓炎
光谱紊乱
肿瘤科
内科学
不利影响
化疗
免疫学
精神科
多发性硬化
作者
Clare Angeli G. Enriquez,Adrian I. Espiritu,Paul Matthew D. Pasco
标识
DOI:10.1016/j.jneuroim.2019.04.007
摘要
The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD). Eight articles were reviewed with a total of 117 patients. Annualized relapse rate and progression of disability dramatically decreased post-treatment in most studies. Mitoxantrone was generally tolerated. Only one patient developed acute myeloid leukemia, which lead to septicemia and death. No serious cardiotoxicity was reported. Mitoxantrone may be effective in reducing the frequency of relapse and slowing down the progression of disability in patients with NMOSD. The risk of cardiotoxicity and leukemia detains it as a second-line agent for NMOSD.
科研通智能强力驱动
Strongly Powered by AbleSci AI